425: Cara Therapeutics to Merge with Tvardi Therapeutics, Focusing on STAT3-Targeting Therapies

Cara Therapeutics and Tvardi Therapeutics have announced a merger agreement, with the combined company focusing on advancing Tvardi's STAT3-targeting therapies for fibrosis-driven diseases.

Summary

• Cara Therapeutics and Tvardi Therapeutics have entered into a merger agreement.
• The combined company will focus on developing Tvardi's novel, oral, small molecule therapies targeting STAT3 for fibrosis-driven diseases.
• The merger is expected to close in the first half of 2025, subject to stockholder approval and customary closing conditions.
• Pro forma company ownership is expected to be 83.0% Tvardi and 17.0% Cara, before giving effect to Tvardi financing.
• The combined company will be well-capitalized, including $28 million from concurrent financing, and is expected to be funded into the second half of 2026.
• Tvardi management will operate the pro forma company, and the combined Board of Directors will include six representatives from Tvardi and one from Cara.
• Key data readouts are expected in the second half of 2025 for IPF and HCC Phase 2 trials.
• An IND submission for TTI-109 is planned for the first half of 2025.

Sentiment

Score: 7

Explanation: The document presents a positive outlook on the merger between Cara Therapeutics and Tvardi Therapeutics, highlighting the potential of Tvardi's STAT3-targeting therapies and the expected near-term data catalysts. The combined company is expected to be well-capitalized, and the management team has deep expertise. However, the document also acknowledges the risks and uncertainties associated with the merger and clinical development, which tempers the overall sentiment.

Positives

• The merger creates a company focused on a promising therapeutic target (STAT3) for fibrosis-driven diseases.
• The combined company is expected to be well-capitalized, providing runway into the second half of 2026.
• Near-term data catalysts are expected with Phase 2 readouts for IPF and HCC in the second half of 2025.
• TTI-101 has shown encouraging trends in lung function in early blinded Phase 2 data.
• TTI-101 has demonstrated durable partial responses in fibrotic tumors in a Phase 1 clinical trial.
• TTI-101 has shown to reverse multiple pathogenic steps of liver cancer in a NASH-induced HCC model.

Negatives

• The merger is subject to stockholder approval and customary closing conditions, which introduces uncertainty.
• The combined company will be reliant on the success of Tvardi's programs, which are still in clinical development.
• The forward-looking statements are subject to risks and uncertainties, and actual results may differ materially.

Risks

• The conditions to the closing of the Merger are not satisfied, including that the approval of the stockholders of Cara is not obtained on the timeline expected, if at all.
• Uncertainties as to the timing of the closing of the Merger and the ability of each of Tvardi and Cara to consummate the Merger.
• Risks related to the ability of Tvardi and Cara to correctly estimate and manage their respective operating expenses and expenses associated with the Merger pending the closing of the Merger.
• Risks associated with the possible failure to realize certain anticipated benefits of the Merger, including with respect to future financial and operating results.
• The potential for the occurrence of any event, change or other circumstance or condition that could give rise to the termination of the Merger and any agreements entered into in connection therewith.
• The possible effect of the announcement, pendency or completion of the Merger on Tvardis or Caras business relationships, operating results and business generally.
• The risk that as a result of adjustments to the exchange ratio, Tvardi stockholders and Cara stockholders could own more or less of the combined company than is currently anticipated.
• Risks related to the market price of Caras common stock relative to the value suggested by the exchange ratio.
• Unexpected costs, charges or expenses resulting from the Merger.
• The uncertainties associated with Tvardis product candidates, as well as risks associated with the clinical development and regulatory approval of product candidates, including potential delays in the completion of clinical trials.
• The significant net losses each of Cara and Tvardi has incurred since inception.
• The combined companys ability to initiate and complete ongoing and planned preclinical studies and clinical trials and advance its product candidates through clinical development.
• The timing of the availability of data from the combined companys clinical trials.
• The outcome of preclinical testing and clinical trials of the combined companys product candidates, including the ability of those trials to satisfy relevant governmental or regulatory requirements.
• The combined companys plans to research, develop and commercialize its current and future product candidates.
• The clinical utility, potential benefits and market acceptance of the combined companys product candidates.
• The requirement for additional capital to continue to advance these product candidates, which may not be available on favorable terms or at all.
• The combined companys ability to attract, hire, and retain skilled executive officers and employees.
• The combined companys ability to protect its intellectual property and proprietary technologies.
• The combined companys reliance on third parties, contract manufacturers, and contract research organizations.
• The possibility that Tvardi, Cara or the combined company may be adversely affected by other economic, business, or competitive factors.
• Risks associated with changes in applicable laws or regulations.

Future Outlook

The combined company will focus on advancing Tvardi's STAT3-targeting therapies, with key data readouts expected in the second half of 2025 and an IND submission planned for the first half of 2025.

Management Comments

• Tvardi management will operate the pro forma company.

Industry Context

The merger reflects a growing interest in targeting STAT3 for fibrosis-driven diseases, as evidenced by Tvardi's focus and the potential for disease-modifying therapies in areas with significant unmet need.

Comparison to Industry Standards

• The document mentions Ofev (nintedanib) and Esbriet (pirfenidone) as FDA-approved drugs for IPF, which have peak sales of $3.8B and $1.1B respectively, indicating the commercial potential of IPF treatments.
• The document references a Phase 2 trial of Danvatirsen (STAT3 ASO) + Durvalumab (ICI) in 2L HNSCC, which had an ORR of 23%, providing a benchmark for combination therapy in oncology.
• The document mentions that the current expected ORR in 2L HCC is <5%, highlighting the unmet need in this area and the potential for TTI-101 to provide a distinct and synergistic mechanism.

Stakeholder Impact

• Shareholders of Cara Therapeutics and Tvardi Therapeutics will be impacted by the merger and the future performance of the combined company.
• Employees of both companies may be affected by the integration of the two organizations.
• Patients with fibrosis-driven diseases could benefit from the development of new therapies targeting STAT3.

Next Steps

• Obtain stockholder approval for the merger.
• Satisfy customary closing conditions.
• Advance TTI-101 through Phase 2 clinical trials for IPF and HCC.
• Submit an IND for TTI-109.
• Rename the combined company to Tvardi Therapeutics, Inc.

Key Dates